ALOX5 and COVID-19: We and others have suggested that in SARS-CoV-2-mediated SDRA, agents such as 5-LO inhibitors could reduce the consequences of virus-induced cytopathic effects by immediate action on critical immune cells, which are associated with cytokine release syndrome in COVID-19 [14].